List of repeatable biomarkers in the lung compartments (for all markers with ICC>0.60). by Stefan Röpcke (129630)

“…To derive the SD value, that together with the median values of a marker (listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046207#pone-0046207-t004" target="_blank">table 4</a> and in the Online Supplement) can be used for sample size and power calculations, the respective median needs to be multiplied and divided by the value listed above (Example for HSA in BAL fluid of COPD patients: Approximate level of HSA in BAL is 11 µg/mL (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046207#pone-0046207-t004" target="_blank">table 4</a>), the SD is 1.5×11–11/1.5 = 16.5–7.3 = 9.2 µg/mL). …”

Table_1_Incidence, Progression, and Patterns of Multimorbidity in Community-Dwelling Middle-Aged Men and Women.docx by Xianwen Shang (311546)

“…The time to develop a subsequent condition decreased with the accumulation of conditions (P < 0.0001). …”

Data_Sheet_1_The Clinical Trial Outcomes of Med-Zenith PT-Valve in the Treatment of Patients With Severe Pulmonary Regurgitation.docx by Xiaoke Shang (3589976)

“…Post-procedural pulmonary artery diastolic pressure increased from 5.8 ± 3.1 to 11.3 ± 2.5 mmHg. In the 3-month and 1-year follow-up, the right ventricular end diastolic volume index reduced from the baseline 181.6 ± 29.0 to 143.7 ± 29.7 ml/m² and 123.4 ± 31.2 ml/m², and the trans-pulmonary valve gradient decreased from 25.6 ± 22.2 to 10.64 ± 3.54 mmHg and 11.16 ± 3.0 mmHg, respectively. …”

The Tree GSPF Level Tree Chronogram of Poison Frogs with Known Taxonomic Diversity (i.e., Numbers within Parentheses) and Significant Diversification Rate Changes for Nodes or Line... by Juan C Santos (267336)

“…The significant increases indicated by a star next to nodes 2 and 9 might be dependent on deeper nodes (i.e., 1 and 5, respectively) and produced by a “trickle-down effect” (see “Lineage Diversification” in Results).…”

The effect of ribavirin (Rib) and guanosine (Gua) on HCV infectious progeny production and intracellular viral RNA and nucleotide pools. by Ana M. Ortega-Prieto (446894)

“…<p>(a) Huh-7.5 reporter cells were infected with HCVp0 at a initial MOI of 0.1–0.2 TCID₅₀/cell, in the absence or presence of the Rib and Gua concentrations indicated in the upper box. …”

Survival and diapause induction. by Mariana Abarca (6792434)

“…<p>A) Probability of survival and B) diapause induction (LS means ± SE) of individuals kept at each of three oscillating temperature regimes (mean ± 5), feeding on either a high quality (green, open circles, kudzu, <i>Pueraria montana</i>) or a low quality (yellow, solid circles, wisteria, <i>Wisteria sinensis</i>) host. …”

Western blot analysis of expression and phosphorylation of wild-type and mutated FGFR4 and its downstream target, STAT3, after treatment with 0, 200, and 800 nM concentrations of p... by Samuel Q. Li (466819)

“…(C-D) Western blot shows a dose-dependent decrease in STAT3 phosphorylation after treatment with ponatinib for three fusion-positive (RH4, RH5, and RH41) and one fusion-negative (CTR) RMS cell lines as well as the two RMS772 cell lines expressing the FGFR4 mutations N535K and V550E.…”

The funnel plot of visual analog scale score. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

Intervention characteristics of included studies. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

GRADE evaluation of evidence quality. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

PRISMA flow diagram. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

Summary data and analyses. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

The funnel plot of Harris hip score. by Guimei Guo (4127074)

“…The change in visual analog scale (VAS) score 3 months post intervention (MD = -0.33, 95% Cl: -0.52 to -0.13, P = 0.001), 6 months (MD = -0.69, 95% Cl: -0.90 to -0.48, P < 0.00001), 12 months (MD = -0.75, 95% Cl: -1.05 to -0.46, P < 0.00001), ≥ 24 months (MD = -1.05, 95% Cl: -1.20 to -0.89, P < 0.00001), and the last follow-up (MD = -0.75, 95% Cl: -0.97 to -0.54, P < 0.00001). The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

Binarized cross recurrence plot of the MT-M1 functional connectivity. by Clara Rodriguez-Sabate (4512394)

“…The PD group shows a decrease of the ON-ON match density in both the resting-task block (Fig 5B) and the motor-task block (Fig 5D).…”

Highly Porous, Hydrophobic, and Compressible Cellulose Nanocrystals/Poly(vinyl alcohol) Aerogels as Recyclable Absorbents for Oil–Water Separation by Xiaoyu Gong (2284477)

“…With the three-dimensional interconnected microstructure, the aerogels were highly porous (porosity >97.7%) and ultralight with a density ranging from 22.5 to 36.1 mg/cm³ and floatable on the water surface. …”

Highly Porous, Hydrophobic, and Compressible Cellulose Nanocrystals/Poly(vinyl alcohol) Aerogels as Recyclable Absorbents for Oil–Water Separation by Xiaoyu Gong (2284477)

“…With the three-dimensional interconnected microstructure, the aerogels were highly porous (porosity >97.7%) and ultralight with a density ranging from 22.5 to 36.1 mg/cm³ and floatable on the water surface. …”

Single-instance population averaging predicts human spatial perception. by Helge Gleiss (7053491)

“…Conventions as in (A). (C) Average D(mean) across all cells (<i>n</i> = 13) decreased for the concurrent HPR, suggesting a relative worsening of the ability to distinguish adjacent ILDs by −15.5% (right-hand panel). …”

Quantitative comparison of protein expression between two <i>P</i>. <i>vivax</i> salivary gland sporozoite field isolates. by Kristian E. Swearingen (2301094)

“…Points in red are proteins with that were not significant at a 5.0% false discovery rate (FDR) according to the G-test. …”

Germination and biochemical changes in West Indian gherkin seeds under water stress at different temperatures by João Paulo Nobre de Almeida (4659739)

“…The experimental design was completely randomized, in 5 x 5 factorial scheme, composed of five osmotic potentials (0.0; -0.1; -0.2; -0.3 and -0.4 MPa) and four temperatures (20; 25; 30 °C and alternating temperatures of 20-30 ºC), with each treatment composed of four replicates of 50 seeds. …”

8oxoG inhibits TRF1 binding to telomeric DNA by Patricia L. Opresko (7493)

“…All rights reserved</p> Boxes indicate the GGG runs of the tandem telomeric repeats, and (X) marks the position of the 8oxoG lesion(s) within the G runs (see ). Substrates (2.5 nM) were incubated alone (−) or together with decreasing concentrations of purified TRF1 (200, 100, 50 or 25 nM) (lanes 2–5, 7–10, and 12–15, 17–20, 22–25 and 27–30) for 20 min at 4°C in TEL buffer. …”